a New Front
in the War against Cancer
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
An Investigational Drug for Cancer
An Investigational Drug for Psoriasis and Atopic Dermatitis
Melanoma News Today covered a paper recently published in Current Opinion in Oncology entitled "Intralesional therapy for advanced melanoma: promise and limitation".
A recent paper in Current Opinion in Oncology states that despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy.
Slides from Provectus' presentation at the BIO CEO and Investor Conference will be available at 3 pm EDT on February 10, 2015.
A BioMedReports article reports on the recently completed FDA meeting for PV-10 phase 3.
Kate's Foundation has posted news, first appearing on inPharmaTechnologist.com, that the Chinese government has granted Provectus a patent protecting a method of making the active pharmaceutical ingredient (API) in PV-10.
Healio reports that Provectus has received allowance from the Chinese Patent Office for an application to protect its synthetic process for producing the small molecule rose bengal, the active pharmaceutical ingredient (API) in PV-10, a melanoma drug candidate.
In a P&T Community article reporting on the Society for Melanoma Research annual meeting, Dr. Merrick Ross discusses how PV-10's mechanism of action may be synergistic with ipilimumab.
in-Pharma Technologist reports that the patent covering synthesis of PV-10 API, recently granted by the Chinese government, enables licensing deals between Provectus and Chinese partners.
Dermwire covers news that the Chinese Patent Office has allowed Provectus' patent application covering the synthesis of PV-10.
In a video appearing on P&T Community, Dr. Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative and who currently don’t have good treatment options.
Peter Culpepper, CFO and COO of Provectus, was recently interviewed by The WallStreet Transcript. In the interview, Mr. Culpepper discusses clinical development status, including a Phase 3 trial of PV-10 for melanoma and Phase 1b/2 trials of PV-10 for liver cancer and PV-10 combined with immune checkpoint blockade agents for melanoma. Mr. Culpepper also answers questions of clinical study time frames, funding, and potential partners.
India West reports on the launch of the American Association of Physicians of Indian Origin's launch of the Global Clinical Trials Network. Provectus has committed to being the inaugural member of the Global Clinical Trial Network.
In-Pharma Technologist reports that Deanna Angello, a Director of Commercial Strategy and New Business Planning within the Global Established Pharma business at Pfizer has joined Provectus' Strategic Advisory Board.
The Mid-Day Changers section of WallStreet Scope for January 8, 2015 reports Provectus as a stock to watch.
Property Mentor Group, in the Top News section for January 8, 2015, reports on Provectus' participation at the Annual American Association of Physicians of Indian Origin Conference in Orlando.
An article appearing in the India Post announces the launch of the AAPI – Global Clinical Trials Network, a new initiative of American Association of Physicians of Indian Origin.
An article titled "AAPI - Global Clinical Trials Network launched during Global Healthcare Summit 2015 in Mumbai" appearing on NRI News announces the launch of the Global Clinical Trials Network, a new initiative of the American Association of Physicians of Indian Origin (AAPI). The new initiative was launched on January 4th, 2015 during the Global Health Care Summit in Mumbai in India. Provectus has committed to be the inaugural member of the Global Clinical Trial network. AAPI is looking forward to creating a large network of Pharmaceutical companies to make this initiative a great success.
An article appearing on Dermwire covers news of Provectus' upcoming meeting with the US FDA to review certain operational aspects of the protocol for a planned phase 3 clinical trial of intralesional PV-10 as a treatment for melanoma. No date for this meeting has been agreed upon as yet.
In an article appearing in Cancer Watch, cancer researchers discuss the promising strategy of combining intralesional drugs such as PV-10, that stimulate an immune response by killing tumor cells in a manner whereby intact antigens are expressed, with drugs such as ipilimumab and pembrolizumab that act as immune checkpoint inhibitors.
In a video interview appearing on decisionplus.com, Peter Culpepper, CFO and COO of Provectus Biopharmaceuticals, discusses the current status of PV-10 development, regulatory events, compassionate care, and global market strategy.
Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.
Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.
Provectus announced today that it will present at the 17th Annual BIO CEO and Investor Conference on Tuesday, February 10,2015.
Provectus announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.
Provectus announced today that an article, entitled "Intralesional therapy for advanced melanoma: promise and limitation," authored by Sanjiv S. Agarwala, MD, has been published in the March issue of Current Opinion in Oncology, now available online.
Provectus announced today that it has opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis.
Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.
Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:
Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.
Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.
Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.
Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.
Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.
Provectus today announced financial results for the third quarter of 2014.
Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.
Provectus announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120.
Provectus will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.
Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.
Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).
Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.